Mark Coleman's most recent trade in Axsome Therapeutics Inc was a trade of 3,166 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 6, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 3,166 | 3,166 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 1,429 | 1,429 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Sale of securities on an exchange or to another person at price $ 105.47 per share. | 27 May 2025 | 3,750 | 50,387 (0%) | 0% | 105.5 | 395,513 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Sale of securities on an exchange or to another person at price $ 103.43 per share. | 27 May 2025 | 3,750 | 46,637 (0%) | 0% | 103.4 | 387,863 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Sale of securities on an exchange or to another person at price $ 107.49 per share. | 20 May 2025 | 3,000 | 54,137 (0%) | 0% | 107.5 | 322,473 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.00 per share. | 03 Jan 2025 | 9,127 | 57,137 (0%) | 0% | 9 | 82,143 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 9,127 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.94 per share. | 19 Nov 2024 | 33,410 | 48,010 (0%) | 0% | 5.9 | 198,455 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2024 | 33,410 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 5,799 | 5,799 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Sale of securities on an exchange or to another person at price $ 75.21 per share. | 28 May 2024 | 5,249 | 19,848 (0%) | 0% | 75.2 | 394,775 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Sale of securities on an exchange or to another person at price $ 75.14 per share. | 28 May 2024 | 5,248 | 14,600 (0%) | 0% | 75.1 | 394,333 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 5,681 | 5,681 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 2,870 | 2,870 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.30 per share. | 03 Jan 2023 | 17,501 | 25,097 (0%) | 0% | 1.3 | 22,751 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 17,501 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 16,976 | 16,976 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.30 per share. | 15 Mar 2022 | 3,496 | 7,596 (0%) | 0% | 1.3 | 4,545 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2022 | 3,496 | 17,501 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 2,798 | 2,798 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Purchase of securities on an exchange or from another person at price $ 35.10 per share. | 18 Nov 2021 | 1,021 | 422,428 (1%) | 0% | 35.1 | 35,837 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Purchase of securities on an exchange or from another person at price $ 35.07 per share. | 18 Nov 2021 | 409 | 421,407 (1%) | 0% | 35.1 | 14,344 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 7,325 | 7,325 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Purchase of securities on an exchange or from another person at price $ 58.15 per share. | 12 May 2021 | 500 | 420,998 (1%) | 0% | 58.2 | 29,075 | Common Stock |
| Axsome Therapeutics Inc | Mark Coleman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2021 | 1,201 | 1,201 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Aug 2020 | 397,998 | 397,998 (1%) | 1% | 0 | Common Stock | |
| Axsome Therapeutics Inc | Mark Coleman | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Aug 2020 | 397,998 | 5,700 (0%) | 1% | 0 | Common Stock |